Trial Profile
A open-label, single sequence, two periods, non-randomized, clinical interaction study between rifapentine and ATRIPLA in HIV and TB free subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Dec 2015
Price :
$35
*
At a glance
- Drugs Rifapentine (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
- Indications HIV infections
- Focus Pharmacokinetics
- 06 Dec 2015 New trial record